RxDoctor Payments DataLook up a doctor →

Ryan Cleary, MD

Urology · Baltimore, MDNPI 1013232693

Payments from drug & device makers

$14,638in general payments, 2019–2025

Across 360 payments — averaging $40.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$7K
  • Johnson & Johnson$1K
  • AbbVie$1K
  • Astellas Pharma US Inc$645
  • Bayer$388
  • Sumitomo Pharma America, Inc.$338
  • plus $4K from 45 others

What the payments were for

  • Travel & lodging$1,0567%
  • Food & beverage$9,34164%
  • Education$4,24129%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,638 in reported general payments places this provider in the 75th percentile of 274 urology providers in Maryland.

See all urology providers in Maryland

Medicare billing

Part B allowed, 2024
$369,834
Medicare patients
768
Services billed
17,682

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide11$166,527
XtandiEnzalutamide11$153,251
MyrbetriqMirabegron81$52,756
GemtesaVibegron57$41,146
Tolterodine Tartrate ErTolterodine Tartrate99$6,140
Mirabegron ErMirabegron12$5,883
Oxybutynin Chloride ErOxybutynin Chloride230$5,302
Tamsulosin Hcl368$4,123
Trospium Chloride ErTrospium Chloride16$2,898
Tadalafil14$2,670
Finasteride140$1,782
Abiraterone Acetate11$1,447
Estradiol21$883
NitrofurantoinNitrofurantoin Macrocrystal28$736
Solifenacin Succinate24$724

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$645$206,00792 claims
Johnson & JohnsonErleada$1,356$166,52711 claims
Sumitomo Pharma America, Inc.Gemtesa$338$41,14657 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$22$1,44711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 274 urology providers in Maryland.

Other urology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →